SCHEMBL1700840

SCHEMBL1700840

CC(NCC(=O)O)C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
PTGS2 P35354 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
ECE1 P42892 1/20 0.38
CYP1A2 P05177 1/20 0.37
MME P08473 2/20 0.36
ACE P12821 2/20 0.36
CPA1 P15085 2/20 0.36
ACE2 Q9BYF1 2/20 0.36
TP53 P04637 1/20 0.36
CTH P32929 1/20 0.36
EGLN1 Q9GZT9 1/20 0.34
LTA4H P09960 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2132525 1.00 ALDH1A1 (0.43) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL2805307 1.00 ALDH1A1 (0.43) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL14056387 0.97 ALDH1A1 (0.41) ALDH1A1LMNAMAPTPTGS2TDP1
Hydrochloric Acid SCHEMBL10578120 0.97 ALDH1A1 (0.41) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL667846 0.97 ALDH1A1 (0.41) ALDH1A1LMNAMAPTPTGS2TDP1
Boric Acid SCHEMBL31168108 0.93 ALDH1A1 (0.39) ALDH1A1LMNAMAPTPTGS2TDP1
Alanine SCHEMBL27729429 0.91 ALDH1A1 (0.38) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL5960119 0.89 BHMT (0.37) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL28627379 0.85 EGLN1 (0.35) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL3442583 0.82 ALDH1A1 (0.36) ALDH1A1LMNAMAPTPTGS2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 541 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260137621-A1 ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS DIASOME PHARMACEUTICALS INC (US) 2026-05-21 US claimed
WO-2025264553-A1 COMPOSITION AND METHOD FOR PERFUSING TISSUE DEKA PRODUCTS LIMITED PARTNERSHIP (US) 2025-12-26 WO claimed
US-20250288521-A1 ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS DIASOME PHARMACEUTICALS INC (US) 2025-09-18 US claimed
US-12343416-B2 Skin engaging member for razor cartridge comprising skin active ingredient BIC-VIOLEX S.A. (GR) 2025-07-01 US claimed
CN-120058757-A Synthesis method of methyl iminodiacetic acid borate compound 上海泰坦科技股份有限公司 2025-05-30 CN claimed
US-20250136488-A1 Extended- and Multimodal-Release Compositions Finoric LLC 2025-05-01 US claimed
CN-119487140-A CMP slurry composition for polishing copper barrier layer YC化工股份有限公司 2025-02-18 CN claimed
CN-117603771-A Stable-viscosity and shear-thinning acidic cleaning agent composition 纳爱斯浙江科技有限公司 2024-02-27 CN claimed
WO-2024010249-A1 CMP SLURRY COMPOSITION FOR POLISHING COPPER BARRIER LAYER 와이씨켐 주식회사 2024-01-11 WO claimed
CN-116262886-A Cleaning agent with stain stripping enhancing effect 纳爱斯浙江科技有限公司 2023-06-16 CN claimed
US-20080044830-A1 Three-Dimensional Nanostructured and Microstructured Supports FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) 2008-02-21 US claimed
EP-1691840-A2 PSMA FORMULATIONS AND USES THEREOF Psma Development Company, L.L.C. (US) 2006-08-23 EP claimed
WO-2005042029-A2 PSMA FORMULATIONS AND USES THEREOF PSMA DEVELOPMENT COMPANY, LLC (US) 2005-05-12 WO claimed
US-20040161776-A1 PSMA formulations and uses thereof PSMA DEVELOPMENT COMPANY, LLC 2004-08-19 US claimed
US-20020090581-A1 Photographic bleach composition and process EASTMAN KODAK COMPANY 2002-07-11 US claimed
EP-1203994-A2 Photographic bleach composition and process EASTMAN KODAK COMPANY (US) 2002-05-08 EP claimed
WO-1999048895-A1 A PROCESS FOR RECOVERY OF 6-AMINOPENICILLANIC ACID FROM A MOTHER LIQUOR DSM N.V. (NL) 1999-09-30 WO claimed
US-5683793-A Ink jet transparencies XEROX CORPORATION (US) 1997-11-04 US claimed
US-5589277-A INK JET PRINTING, AQUEOUS INKS, FAST DRYING XEROX CORPORATION (US) 1996-12-31 US claimed
EP-0667246-A1 Recording sheets containing amino acids, hydroxy acids, and polycarboxyl compounds XEROX CORPORATION (US) 1995-08-16 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250288521-A1 ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS FABP2, FABP1, FABP6 ALDH1A1 2309/4885LMNA 1568/4885MAPT 3275/4885
US-12343416-B2 Skin engaging member for razor cartridge comprising skin active ingredient CUTA, SHARPIN, MMP11 ALDH1A1 2608/4885LMNA 1249/4885MAPT 3729/4885
US-20260137621-A1 ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS FABP2, FABP1, SGMS2 ALDH1A1 3684/4885LMNA 1721/4885MAPT 3628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.